In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.
- 1 January 2002
- journal article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 19 (5), 588-594
- https://doi.org/10.1023/a:1015341726183
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The legacy of pharmacogenetics and potential applicationsMutation Research, 2001
- In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.2001
- Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.2001
- Isolation and Characterization of the UGT2B28 cDNA Encoding a Novel Human Steroid Conjugating UDP-GlucuronosyltransferaseBiochemistry, 2001
- Human UDP-Glucuronosyltransferases: Metabolism, Expression, and DiseaseAnnual Review of Pharmacology and Toxicology, 2000
- The Monkey and Human Uridine Diphosphate-Glucuronosyltransferase UGT1A9, Expressed in Steroid Target Tissues, Are Estrogen-Conjugating Enzymes*Endocrinology, 1999
- STRUCTURAL AND FUNCTIONAL STUDIES OF UDP-GLUCURONOSYLTRANSFERASES*Drug Metabolism Reviews, 1999
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.Journal of Clinical Oncology, 1998
- Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.1996
- Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates.1994